Get the Stockscreener App
76.97
0.33%
0.13
Cytokinetics Inc stock is traded at $76.97, with a volume of 597.19K.
It is up +0.33% in the last 24 hours and down -4.52% over the past month.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$76.84
Open:
$77.2
24h Volume:
597.19K
Relative Volume:
0.30
Market Cap:
$10.71B
Revenue:
$105.82M
Net Income/Loss:
$-829.61M
P/E Ratio:
-11.25
EPS:
-6.8429
Net Cash Flow:
$-548.92M
1W Performance:
+1.61%
1M Performance:
-4.52%
6M Performance:
+9.97%
1Y Performance:
+101.07%
1-Day Range:
$75.65
$77.99
1-Week Range:
$74.76
$77.99
52-Week Range:
$35.22
$88.31
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
77.01 | 10.73B | 105.82M | -829.61M | -548.92M | -6.8429 |
VRTX
Vertex Pharmaceuticals Inc
|
549.38 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
826.30 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,014.91 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.31 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.55 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Wells Fargo | Overweight |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Dec-18-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-30-25 | Resumed | Raymond James | Mkt Perform |
| Apr-24-25 | Initiated | Barclays | Overweight |
| Feb-07-25 | Initiated | Citigroup | Buy |
| Jan-22-25 | Initiated | Stifel | Buy |
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Cytokinetics to Present ACACIA-HCM Hot Line Results and Host Investor Event at ESC Congress 2026 - Quiver Quantitative
Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) ... - Caledonian Record
Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 - Yahoo Finance
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock? - Yahoo Finance
Cytokinetics (CYTK) EVP Research & Development Fady Malik Sells 3,500 Shares - GuruFocus
Cytokinetics EVP Fady Ibraham Exercises Stock Options and Sells 3,500 Shares Under Rule 10b5-1 Plan - Kalkine Media
Cytokinetics EVP research & development sells $265,370 in stock By Investing.com - Investing.com Nigeria
Cytokinetics EVP research & development sells $265,370 in stock - Investing.com
Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells $265,370.00 in Stock - MarketBeat
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
symbol__ Stock Quote Price and Forecast - CNN
Will MYQORZO Traction Amid Weaker Q2 2026 Results Change Cytokinetics' (CYTK) Narrative - webull.com
Cytokinetics (NASDAQ:CYTK) Raised to Hold at Wall Street Zen - MarketBeat
H.C. Wainwright reiterates Cytokinetics stock rating on patent suit By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Cytokinetics stock rating on patent suit - Investing.com
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers - Yahoo Finance
Cytokinetics (CYTK) Q2 2026 Earnings Call Transcript - AOL.com
Cytokinetics files patent lawsuit against Bristol-Myers Squibb over heart drug - The Business Journals
Wellington group discloses over 5% Cytokinetics (CYTK) holding for clients - Stock Titan
CYTK Maintained by Barclays -- Price Target Raised to $110 - GuruFocus
CYTK Looks 60.3% Undervalued on GF Value™ Despite Legal Dispute - GuruFocus
CYTK Maintained by JP Morgan -- Price Target Raised to $103 - GuruFocus
JPMorgan Chase & Co. Raises Cytokinetics (NASDAQ:CYTK) Price Target to $103.00 - MarketBeat
Cytokinetics sues Bristol-Myers in patent case (CYTK:NASDAQ) - Seeking Alpha
Form 8K Cytokinetics Inc For: 13 August By Investing.com - Investing.com Nigeria
Cytokinetics files lawsuit seeking patent judgment against Bristol-Myers Squibb - Investing.com South Africa
Cytokinetics Initiates Legal Action Challenging Patent on MYQORZO (Aficamten) - Kalkine Media
PD Small-Cap Value Index Portfolio's Cytokinetics Inc(CYTK) Holding History - GuruFocus
Barclays raises Cytokinetics stock price target on strong Myqorzo sales - Investing.com
Barclays raises Cytokinetics stock price target on strong Myqorzo sales By Investing.com - Investing.com Australia
Cytokinetics, Incorporated $CYTK Shares Purchased by Tema ETFs LLC - MarketBeat
Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo Finance
Handelsbanken Fonder AB Grows Stock Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics Inc (CYTK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dimensional Fund Advisors LP Has $6.23 Million Stock Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics president & CEO Robert Blum sells $575,700 in shares By Investing.com - Investing.com UK
Cytokinetics Insider Sold Shares Worth $575,700, According to a Recent SEC Filing - moomoo.com
HC Wainwright Raises Earnings Estimates for Cytokinetics - MarketBeat
Cytokinetics, Incorporated (CYTK) Stock forecasts - Yahoo Finance UK
Cytokinetics president & CEO Robert Blum sells $575,700 in shares - Investing.com
Insider Selling: Cytokinetics (NASDAQ:CYTK) CEO Sells $575,700.00 in Stock - MarketBeat
Cytokinetics, Incorporated Revenue Breakdown – NASDAQ:CYTK - TradingView
CYTOKINETICS, INCORPORATED : LEERINK PARTNERS RAISES TARGET PRICE TO $103 FROM $100 - Bitget
CYTOKINETICS, INCORPORATED : TRUIST SECURITIES RAISES TARGET PRICE TO $112 FROM $106 - Bitget
Truist Adjusts Price Target on Cytokinetics to $112 From $106, Maintains Buy Rating - marketscreener.com
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytokinetics Inc Stock (CYTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Aug 18 '26 |
Sale |
75.82 |
3,500 |
265,370 |
153,902 |
| Blum Robert I | President & CEO |
Aug 10 '26 |
Option Exercise |
10.60 |
7,500 |
79,500 |
385,320 |
| Blum Robert I | President & CEO |
Aug 10 '26 |
Sale |
76.76 |
7,500 |
575,700 |
377,820 |
| Callos Andrew | EVP, Chief Commercial Officer |
Jul 30 '26 |
Option Exercise |
23.26 |
14,000 |
325,640 |
72,555 |
| Callos Andrew | EVP, Chief Commercial Officer |
Jul 30 '26 |
Sale |
79.88 |
14,000 |
1,118,320 |
58,555 |
1.18%
0.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):